Results 101 to 110 of about 12,370,091 (268)

A scientometric analysis of CGRP and CGRP receptors in migraine research: trends, impact, and therapeutic potential

Headache Medicine
Calcitonin gene-related peptide (CGRP) and CGRP receptors, present in the trigeminovascular system, are found in high concentrations in the jugular plasma during headache attacks.
Gabriela Faria de Oliveira, Marcos Vinicius Pupo, Kádima Nayara Teixeira , Ana Paula Carneiro Brandalize   +3 more
doaj   +2 more sources

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

The Journal of Headache and Pain, 2019
Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine.
Valentina Favoni, Luca Giani, Linda Al-Hassany, Gian Maria Asioli, Calogera Butera, Irene de Boer, Martina Guglielmetti, Chrysoula Koniari, Theodoros Mavridis, Marge Vaikjärv, Iris Verhagen, Angela Verzina, Bart Zick, Paolo Martelletti, Simona Sacco, European Headache Federation School of Advanced Studies (EHF-SAS)   +15 more
doaj   +1 more source

Calcitonin gene related peptide stimulates differentiation of neonatal rat myogenic cultures

, 1993
The effect of the nerve derived peptide, calcitonin gene related peptide (CGRP) on myoblast fusion/differentiation was studied in rat myogenic cell cultures, using creatine kinase activity as an index of fusion.
Noble, B.S., McMillan, D.N., Maltin, C.A.   +2 more
core  

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja   +5 more
wiley   +1 more source

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

New England Journal of Medicine, 2019
Calcitonin gene-related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene-related peptide receptor antagonist that may be effective in acute migraine treatment.In a multicenter, double-blind, phase 3 trial, we randomly assigned adults with at least a 1-year ...
Richard B. Lipton, Robert Croop, Elyse G. Stock, David A. Stock, Beth A. Morris, Marianne Frost, Gene M. Dubowchik, Charles M. Conway, Vladimir Coric, Peter J. Goadsby   +9 more
openaire   +3 more sources

The effect of capsaicin on expression patterns of CGRP in trigeminal ganglion and trigeminal nucleus caudalis following experimental tooth movement in rats

Journal of Applied Oral Science
Objectives The aim of this study was to explore the effect of capsaicin on expression patterns of calcitonin gene-related peptide (CGRP) in the trigeminal ganglion (TG) and trigeminal subnucleus caudalis (Vc) following experimental tooth movement ...
Yang ZHOU, Hu LONG, Niansong YE, Lina LIAO, Xin YANG, Fan JIAN, Yan WANG, Wenli LAI   +7 more
doaj   +1 more source

Triptans and CGRP blockade – impact on the cranial vasculature

The Journal of Headache and Pain, 2017
The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP),
Silvia Benemei, Francesca Cortese, Alejandro Labastida-Ramírez, Francesca Marchese, Lanfranco Pellesi, Michele Romoli, Anne Luise Vollesen, Christian Lampl, Messoud Ashina, On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS)   +9 more
doaj   +1 more source

Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine–Diary (AIM‐D) individual and activity limitation items, and complete improvement in AIM‐D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 ...
Richard B. Lipton, Pranav Gandhi, Andreas R. Gantenbein, Brett Dabruzzo, Karen Carr, Jonathan Stokes, Molly Duan, Rashmi B. Halker Singh, Hsiangkuo Yuan, Dawn C. Buse   +9 more
wiley   +1 more source

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno, Tyla I. Alexander, William K. Karlsson, Haidar M. Al‐Khazali, Michael L. Garelja, Rune H. Christensen, Messoud Ashina, Debbie L. Hay, Håkan Ashina   +8 more
wiley   +1 more source

Calcitonin and calcitonin receptors [PDF]

, 2007
Calcitonin (CT) is a polypeptide hormone with 32 aminoacids syntetized primarily by the thyroid. Several evidences support the existence of nonthyroidal CT like peptide.
Masi, Laura, Brandi, Maria Luisa
core   +1 more source